



PRESTO

P2X REceptors as Therapeutic Opportunity

PUBLICATIONS

1. Illes P, Di Virgilio F, Tang Y. Editorial - Purinergic signalling: 50 years. **Neuropharmacology**, **2023**, 20:109826. doi: 10.1016/j.neuropharm.2023.109826.
2. Tattersall L, Agrawal A, Adinolfi E, Gartland A. EU COST Action CA21130 PRESTO 'P2X receptors as therapeutic targets' inaugural meeting report. **Purinergic Signalling**, **2023**, 19:599. doi: 10.1007/s11302-023-09954-x.
3. Jia W, Huang Z, Zhou L, Liou YC, Di Virgilio F, Ulrich H, Illes P, Zhang W, Huang C, Tang Y. Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies. **Drug Resistance Updates**, **2023**, 70:100988. doi: 10.1016/j.drug.2023.100988.
4. Gilibert D, Duveau A, Carracedo S, Linck N, Langla A, Muramatsu R, Koch-Nolte F, Rassendren F, Grutter T, Fossat P, Boué-Grabot E, Ulmann L. Microglial P2X4 receptors are essential for spinal neurons hyperexcitability and tactile allodynia in male and female neuropathic mice. **iScience**, **2023**, 2:108110. doi: 10.1016/j.isci.2023.108110.
5. Adinolfi E, De Marchi E, Grignolo M, Szymczak B, Pegoraro A. The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk. **International Journal of Molecular Sciences**, **2023**, 18:13906. doi: 10.3390/ijms241813906.
6. Grassi F, Salina G. The P2X7 Receptor in Autoimmunity. **International Journal of Molecular Sciences**, **2023**, 18:14116. doi: 10.3390/ijms241814116.
7. Martínez-Banaclocha H, García-Palenciano C, Martínez-Alarcón L, Amores-Iniesta J, Martín-Sánchez F, Ercole GA, González-Lisorge A, Fernández-Pacheco J, Martínez-Gil P, Padilla-Rodríguez J, Baroja-Mazo A, Pelegrín P, Martínez-García JJ. Purinergic P2X7 receptor expression increases in leukocytes from intra-abdominal septic patients. **Frontiers in Immunology**, **2023**, 14:1297249. doi: 10.3389/fimmu.2023.1297249.
8. Angosto-Bazarra D, Guijarro A, Pelegrín P. Evolution of the gasdermin family and pyroptosis. **Developmental & Comparative Immunology**, **2023**, 149:105060. doi: 10.1016/j.dci.2023.105060.
9. Cevoli F, Arnould B, Peralta FA, Grutter T. Untangling Macropore Formation and Current Facilitation in P2X7. **International Journal of Molecular Sciences**, **2023**, 13:10896. doi: 10.3390/ijms241310896.
10. Del Carmen Gonzalez-Montelongo M, Meades JL, Fortuny-Gomez A, Fountain SJ. Neuropeptide Y: Direct vasoconstrictor and facilitatory effects on P2X1 receptor-dependent vasoconstriction in human small abdominal arteries. **Vascular Pharmacology**, **2023**, 151:107192. doi: 10.1016/j.vph.2023.107192.
11. Rupert M, Bhattacharya A, Sivcev S, Knezu M, Cimicka J, Zemkova H. Identification of residues in the first transmembrane domain of the P2X7 that regulates receptor trafficking, sensitization, and dye uptake function. **Journal of Neurochemistry**, **2023**, 165: 874. <https://doi.org/10.1111/jnc.15813>
12. Abad C, Demeules M, Guillou C, Gondé H, Zoubairi R, Tan YV, Pinto-Espinoza C, Schäfer W, Mann AM, Vouret-Craviari V, Koch-Nolte F, Adriouch S. Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice. **Journal of Nanobiotechnology**, **2024**, 1:27. doi: 10.1186/s12951-023-02285-4.



PRESTO

P2X REceptorS as Therapeutic Opportunity

13. Vouret-Craviari V et al., Activation of the P2RX7/IL-18 pathway in immune cells attenuates lung fibrosis. *Accepted for publication in eLife*, **2024**, doi: 10.7554/eLife.88138.
14. Iring A, Baranyi M, Iring-Varga B, Mut-Arbona P, Gál ZT, Nagy D, Hricisák L, Varga J, Benyó Z, Sperlágh B. Blood oxygen regulation via P2Y12R expressed in the carotid body. **Respiratory Research**, **2024**, 25, 61. <https://doi.org/10.1186/s12931-024-02680-x>.
15. Ghiasi SM, Christensen NM, Pedersen PA, Skovhøj EZ, Novak I. Imaging of extracellular and intracellular ATP in pancreatic beta cells reveals correlation between glucose metabolism and purinergic signalling. **Cellular Signalling**, **2024**, doi: 10.1016/j.cellsig.2024.111109.
16. Magni L, Yu H, Christensen NM, Poulsen MH, Frueh A, Deshar G, Johansen AZ, Johansen JS, Pless SA, Jørgensen NR, Novak I. Human P2X7 receptor variants Gly150Arg and Arg276His polymorphisms have differential effects on risk association and cellular functions in pancreatic cancer. **Cancer Cell International**, **2024**, doi: 10.1186/s12935-024-03339-9
17. Janho Dit Hreich S, Humbert O, Pacé-Loscos T, Schiappa R, Juhel T, Ilié M, Ferrari V, Benzaquen J, Hofman P, Vouret-Craviari V. Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation. **Cancers (Basel)**, **2024**, 16:2226. doi: 10.3390/cancers16122226.
18. Pegoraro A, Grignolo M, Ruo L, Ricci L, Adinolfi E. P2X7 Variants in Pathophysiology. **International Journal of Molecular Sciences**, **2024**, 25:6673. doi: 10.3390/ijms25126673.

List published in July 2024.

Year 2: Grant Period, November 1st, 2023 – October 31st, 2024